Next 10 |
2024-05-08 13:53:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tango Therapeutics (NASDAQ: TNGX ) just reported results for the first quarter of 2024. Tango Therapeutics reported earnings per share of -35 cents. This was below the ana...
2024-05-08 09:52:13 ET More on Tango Therapeutics Seeking Alpha’s Quant Rating on Tango Therapeutics Historical earnings data for Tango Therapeutics Financial information for Tango Therapeutics Read the full article on Seeking Alpha For further...
– Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation...
2024-03-19 17:37:35 ET Gainers: Taysha Gene Therapies ( TSHA ) +32% . Canopy Growth Corporation ( CGC ) +14% . Sarcos Technology and Robotics ( STRC ) +12% . Adicet ( ACET ) +6% . Bridger Aerospace Group Holdings ( BAER ) +4%...
2024-03-18 07:11:07 ET More on Tango Therapeutics Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs Tango Therapeutics Must Produce Its Own Data To Justify Its Valuation Seeking Alpha’s Quant Rating on Tango Therapeutics His...
– Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 phase 1/2 clinical data expected in 2024 – – First patient dosed in phase 1/2 clinical trial of TNG348 in patients with BRCA1/2-mutant and other HRD+ cancers – –...
2024-03-16 02:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that one abstract has been selected for an oral minisymposium and s...
2024-02-13 05:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-07 08:55:30 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – February 7, 2024 – USA News Group – One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer ...
News, Short Squeeze, Breakout and More Instantly...
Tango Therapeutics Inc. Company Name:
TNGX Stock Symbol:
NASDAQ Market:
– Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation...
– Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 phase 1/2 clinical data expected in 2024 – – First patient dosed in phase 1/2 clinical trial of TNG348 in patients with BRCA1/2-mutant and other HRD+ cancers – –...